Search Results
May 05, 2026, 10:00 ET AI Model Analyses Body Composition to Predict Health Risks
help improve risk stratification in oncology or distinguish desirable fat loss from unwanted muscle loss in patients using weight-loss drugs such as GLP–1 agonists."We're already imaging patients every day," Dr. Weiss noted. "On every scan of the abdomen or chest, the information is there, we just
More news about: Radiological Society of North America (RSNA)
May 05, 2026, 10:00 ET AI Model Analyses Body Composition to Predict Health Risks
help improve risk stratification in oncology or distinguish desirable fat loss from unwanted muscle loss in patients using weight-loss drugs such as GLP–1 agonists."We're already imaging patients every day," Dr. Weiss noted. "On every scan of the abdomen or chest, the information is there, we just
More news about: Radiological Society of North America (RSNA)
May 05, 2026, 09:39 ET MyNetDiary Launches GLP-1 Companion for Ozempic, Wegovy, and Mounjaro Users
RD-written GLP-1 content.Unlike basic GLP-1 medication trackers and free GLP-1 add-ons, GLP-1 Companion is built on the depth of MyNetDiary's full nutrition platform: protein elevated as a primary nutrient, dietitian-designed GLP-1 meal plans,
More news about: MyNetDiary Inc
May 05, 2026, 09:00 ET New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions
a distinct profile - defined by faster gastric emptying and lower natural GLP-1 levels - achieved 21.5% TBWL at six months, nearly double the weight loss seen in patients with more typical GLP-1 levels and gastric emptying rates (approximately 10-12%; p=0.0001).Together,
More news about: Phenomix Sciences
May 05, 2026, 08:20 ET BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline
More news about: BrightGene
May 05, 2026, 08:11 ET New toolkit for obesity care helps clinicians integrate lifestyle interventions with obesity medications
ST. LOUIS, May 5, 2026 /PRNewswire/ -- As the use of obesity medications, such as GLP-1 receptor agonists, continues to expand, the American College of Lifestyle Medicine (ACLM) has released a new
More news about: American College of Lifestyle Medicine
May 05, 2026, 07:05 ET Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor
More news about: Viking Therapeutics, Inc.
May 04, 2026, 12:00 ET Conagra Brands Releases Fiscal 2025 Citizenship Report, Detailing Progress Across Key Sustainability Priorities
choice by introducing new front-of-pack communication on select products—including Healthy Choice being the first major brand to communicate "GLP-1 Friendly" on the front of pack in fiscal 2025.100% of Conagra production facilities completed Global Food Safety Initiative (GFSI)-recognized
More news about: Conagra Brands, Inc.
May 04, 2026, 11:40 ET SGS Acquires Keystone Bioanalytical, Strengthening End-to-End Drug Development Lifecycle Testing Capabilities for North American Pharma and Biotech Industries
"Expanding our GLP‑compliant, bioanalysis-focused capabilities within the SGS North American network underscores our commitment to meeting the growing demand for high‑quality
More news about: SGS
May 04, 2026, 08:40 ET Parker Waichman LLP Files Lawsuit on behalf of South Carolina Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
May 04, 2026, 08:00 ET Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
currently in clinical development for a variety of other indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. For full Prescribing Information and other resources, please visit
More news about: Vanda Pharmaceuticals Inc.
May 04, 2026, 07:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
strategy includes multiple programs in preclinical development. NBIP-'1968 is an internally discovered, investigational triple agonist targeting GLP-1, GIP, and glucagon receptors and is intended for use in combination with NBIP-'2118, with the goal of achieving greater weight loss while maintaining
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 07:00 ET Weight-Loss Drugs' Gains Lift Pharma R&D Returns, but 'Bubble' Risk Grows
Returns improved again: Projected IRR increased to 7% in 2025 from 5.9% in 2024.GLP‑1s drive the rebound: GLP‑1 assets represent ~38% of projected commercial inflows; excluding the GLP‑1 class, projected IRR falls to 2.9%.Obesity leads pipeline value: Obesity assets now account
More news about: Deloitte
May 01, 2026, 16:35 ET Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
currently in clinical development for a variety of other indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. For full Prescribing Information and other resources, please visit
More news about: Vanda Pharmaceuticals Inc.
May 01, 2026, 11:00 ET ImpediMed Broadens Breast Cancer Survivorship Monitoring with the SOZO® Digital Health Platform at ASBrS 2026
Breast Clinics" — Kristin Lupton, PA-C; David Weintritt, MD, FACS (Virginia Cancer Specialists)"Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) Use During Endocrine Therapy for Breast Cancer" — Morgan Gary, DMSc, PA-C (CARTI Cancer Center)"Performance of Bioimpedance Spectroscopy for
More news about: ImpediMed
May 01, 2026, 08:04 ET Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US
branding, Ozempic® will be available in a pillOzempic® (semaglutide) pill is the only oral GLP-1 medicine approved for both primary and secondary cardiovascular risk reduction of heart attack, stroke, and death in adults with type 2 diabetes
More news about: Novo Nordisk
May 01, 2026, 07:00 ET Harris Teeter Offers GLP-1 Medications, Nutrition Support and Cost-Saving Options
MATTHEWS, N.C., May 1, 2026 /PRNewswire/ -- Harris Teeter customers can now find expanded GLP-1 offerings and other weight management medications at Harris Teeter Pharmacies across markets, supporting customers with convenient, connected access
More news about: Harris Teeter
May 01, 2026, 00:14 ET Victory Square Technologies Reports Fiscal 2025 Results Highlighting Platform Scaling, Healthcare Infrastructure Growth and Portfolio Momentum
scaling of VSDHOne, Hydreight's infrastructure platform enabling compliant healthcare delivery across multiple verticals including GLP-1 therapies, peptides, hormone optimization, diagnostics, and wellness programs.Hydreight operates a national digital healthcare platform that
More news about: Victory Square Technologies Inc
Apr 30, 2026, 20:56 ET Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale
consultation and platform commissionsPharmacy salesGrowth was supported by:Expansion of product offerings (GLP-1s, peptides, NAD, TRT, and more)Increased partner utilizationBroader adoption across wellness verticalsPROFITABILITY
More news about: Hydreight Technologies Inc.
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
cafraglutide, AMG 133)MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR) featuring monthly or less frequent dosing.MARITIME-1,
More news about: Amgen
Apr 30, 2026, 17:30 ET CELEB BRANDS AND THE NATION'S TOP RETAILERS CONVERGED AT THE 2026 BEVERAGE FORUM TO DISCUSS WHAT TRENDS WILL SHAPE THE INDUSTRY'S NEXT CHAPTER
Circana highlighted the uptick in beverage products that support GLP-1 lifestyles noting, "The demand for nutritional drinks and shakes are continuing to drive innovation, with Kate Farms generating $19.5M and Atkins
More news about: The Beverage Forum
Apr 30, 2026, 15:49 ET Wegovy® é mais eficiente em preservar massa muscular durante a perda de peso, mostram novos estudos de vida real
anos com IMC inicial no percentil 95 ou superior para a idade e gênero (obesidade) e peso corporal acima de 60 kg. Trata-se do primeiro análogo de GLP-1 semanal aprovado pela Anvisa para tratar pessoas com obesidade e sobrepeso com ao menos uma comorbidade relacionada, além de primeiro e único tratamento
More news about: Novo Nordisk
Apr 30, 2026, 13:03 ET Green Boy Invests in Fudi Protein: The Next Generation of Plant-Based Protein via Alfalfa
amongst the proteins and enters the market at a time when consumer interest in protein is skyrocketing, driven in large part by the rise of GLP-1 users whose diets are shifting toward higher protein and fiber intake. A complete and sustainable RuBisCO protein that can rival dairy and animal
More news about: Green Boy Group
Apr 30, 2026, 08:51 ET U.S. Prescription Drug Spending Poised to Cross $1 Trillion
each — more than double the $29 billion spent on the third-highest, apixaban, a blood thinner widely used to prevent strokes and blood clots."GLP-1s have fundamentally reshaped the drug-spending landscape," said Eric Tichy, PharmD, MBA, lead author of the report and division chair of supply chain
More news about: ASHP (American Society of Health-System Pharmacists)
Apr 30, 2026, 07:00 ET RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.